Jazz Pharmaceuticals JAZZ Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| —— | $560.12M+35.0% | $414.83M+285% | -$224.06M+32.0% | ||
| $41.64M+27.1% | $32.75M+7.7% | $30.41M+0.4% | $30.3M+13.4% | ||
| $291.13M+17.4% | $248.05M+9.3% | $226.84M+2.2% | $222M+17.5% | ||
| -$444.97M-114% | -$208.33M+19.9% | -$260.22M+11.0% | -$292.25M— | ||
| —— | $0— | —— | -$37.7M— | ||
| $106.28M+384% | $21.98M-57.6% | $51.88M-42.4% | $90.14M-9.5% | ||
| $93.76M+106% | $45.54M+239% | $13.42M-73.4% | $50.46M+3.3% | ||
| —— | —— | —— | —— | ||
| $77.1M— | —— | —— | $165.99M+16.6% | ||
| -$29.03M-158% | $49.82M— | —— | $24.04M+3,042% | ||
| $28.02M+168% | -$41.26M-74.8% | -$23.6M-107% | -$11.4M-130% | ||
| —— | -$19.62M— | —— | —— | ||
| —— | -$14.74M— | —— | —— | ||
| $654.61M+4.4% | $627.31M+3.1% | $608.28M— | —— | ||
| $1.36B-2.9% | $1.4B+27.8% | $1.09B-14.1% | $1.27B+63.4% | ||
| $58.75M+54.3% | $38.07M+58.9% | $23.96M— | —— | ||
| $1.83B+40.2% | $1.31B+235% | $390.1M+539% | $61.04M+128% | ||
| $1.36B+60.9% | $845M+213% | $270M+350% | $60M— | ||
| —— | $0— | —— | $53M— | ||
| $108.5M— | $0— | $0— | —— | ||
| -$1.51B— | —— | —— | -$450.83M+91.4% | ||
| $107.86M+422% | $20.65M-55.6% | $46.46M-52.6% | $98.02M-27.5% | ||
| $75.22M+30.2% | $57.75M+13.3% | $50.95M+12.1% | $45.44M+27.6% | ||
| -$948.82M— | —— | -$305.25M— | —— | ||
| $6.56M+491% | -$1.68M-247% | $1.14M— | —— | ||
| —— | $906.55M+45.1% | $624.83M+115% | $290.03M+162% | ||
| $248.55M-21.0% | $314.82M-5.5% | $333.11M+23.1% | $270.67M+95.8% | ||
| $121.81M+6.0% | $114.91M-35.4% | $177.88M+87.9% | $94.68M-65.1% | ||
| $654.61M+4.4% | $627.31M+3.1% | $608.28M+1.5% | $599.17M+14.0% | ||
| $41.64M+27.1% | $32.75M+7.7% | $30.41M+0.4% | $30.3M+13.4% | ||
| —— | —— | —— | —— | ||
| —— | —— | $127.12M+450% | -$36.3M-144% | ||
| $147.95M+9.6% | $135.01M-10.9% | $151.45M-44.6% | $273.39M+22.6% | ||
| $32.54M+48.1% | $21.97M-1.8% | $22.38M-41.1% | $37.97M-59.0% | ||
| —— | -$19.62M— | —— | $36.34M— | ||
| $19.11M-31.2% | $27.76M+150% | $11.11M-23.6% | $14.54M-26.1% | ||
| $0— | $0-100% | $61.01M— | $0— | ||
| $108.5M— | $0— | $0-100% | $43.75M+145% | ||
| —— | —— | —— | —— | ||
| $1.36B+60.9% | $845M+213% | $270M+350% | $60M— | ||
| —— | $0— | $0— | —— | ||
| $107.86M+422% | $20.65M-55.6% | $46.46M-52.6% | $98.02M-27.5% | ||
| $781M+2,419% | $31M0.0% | $31M-94.7% | $582.01M-47.2% | ||
| $121.81M+6.0% | $114.91M-35.4% | $177.88M— | —— | ||
| $1.3B-4.5% | $1.36B+27.1% | $1.07B-14.1% | $1.24B+65.5% | ||
| $1.3B-4.5% | $1.36B+27.1% | $1.07B-14.1% | $1.24B+65.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Jazz Pharmaceuticals generate?
- Jazz Pharmaceuticals (JAZZ) generated $1.3B in operating cash flow over the trailing twelve months.
- What is Jazz Pharmaceuticals's free cash flow?
- After $64.6M of capital expenditures, Jazz Pharmaceuticals's free cash flow was $1.3B over the trailing twelve months, down 16.1% year over year.
- Where does Jazz Pharmaceuticals's cash flow data come from?
- Every line is extracted from Jazz Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
